cilgavimab and tixagevimab (Evusheld) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
ACTIV-3/TICO (tixa) NCT04501978		RCT	cilgavimab and tixagevimab (Evusheld)	placebo	COVID 19 hospitalized	some concern	710/707	suggested	suggested 30 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias inconclusive 8 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis